⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012)

Jiwon Oh Anastasiia Raievska Malgorzata Sierzega João Cerqueira Claire Riley Maresa Caunt John N. Ratchford Alexandra Goodyear Konstantina Vanevski Maria Pia Sormani Gavin Giovannoni

View at Publisher

Ask AI

Bookmark

Share

Abstract

To compare the safety and tolerability of fenebrutinib in people with multiple sclerosis (MS) and those with autoimmune indications (AIs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oh et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcb5b6db643587676e99 https://doi.org/10.1212/wnl.0000000000205291

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)Human Clinical Trial · 2026 · 1 citations
2Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)2024 · 2 citations
3Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)Late-Phase Clinical Trial · 2026 · 1 citations
4A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants.RCT · 2026 · 1 citations
5A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B) (P10-6.011)2024

More related papers

Effect on neutrophil migration and antimicrobial functions by the Bruton’s tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib2024
Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation2026
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)2026

More from Neurology

Blood-Based Biomarkers as Predictors of All-Cause DementiaFri,
Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,